@amtejani.bsky.social
Reposted
This project was a part of our multi-year DIAL Study to investigate, "Deintensifying Diabetes Management for Older Adults Living in Long-Term Care". Learn more about the DIAL study here:
buff.ly/x6o51mW
Find deprescribing.org's antihyperglycemic #deprescribing resources here:
buff.ly/TaViSam
buff.ly/x6o51mW
Find deprescribing.org's antihyperglycemic #deprescribing resources here:
buff.ly/TaViSam
Deintensifying Diabetes Management for Older Adults Living in Long-Term Care - Deprescribing.org
Over 25% of older adults living in long-term care (LTC) have diabetes. In Ontario, more than half of LTC residents with diabetes are treated too strictly (i.e. A1c < 7%). This puts residents at risk…
deprescribing.org
December 11, 2025 at 5:01 PM
This project was a part of our multi-year DIAL Study to investigate, "Deintensifying Diabetes Management for Older Adults Living in Long-Term Care". Learn more about the DIAL study here:
buff.ly/x6o51mW
Find deprescribing.org's antihyperglycemic #deprescribing resources here:
buff.ly/TaViSam
buff.ly/x6o51mW
Find deprescribing.org's antihyperglycemic #deprescribing resources here:
buff.ly/TaViSam
Reposted
Shared decision-making is key to successful deprescribing interventions that reflect the goals and priorities of patients and their care partners.
Find our newly updated deprescribing.org shared-decision making tools here:
lnkd.in/gQAX4fGi
Find our newly updated deprescribing.org shared-decision making tools here:
lnkd.in/gQAX4fGi
Deprescribing.org - Optimizing Medication Use
Deprescribing.org - reducing medications safely to meet life’s changes. Online resources for clinicians and patients to help with deprescribing.
deprescribing.org
December 13, 2025 at 5:34 PM
Shared decision-making is key to successful deprescribing interventions that reflect the goals and priorities of patients and their care partners.
Find our newly updated deprescribing.org shared-decision making tools here:
lnkd.in/gQAX4fGi
Find our newly updated deprescribing.org shared-decision making tools here:
lnkd.in/gQAX4fGi
Reposted
Gabapentinoid #deprescribing guidelines are being currently developed by Danijela Gnjidic's team at @sydney.edu.au. Find their project listed on our Deprescribing Guidelines Repository (DEPOT) here:
buff.ly/OCTfpeI
buff.ly/OCTfpeI
Deprescribing Guidelines Repository (DEPOT) - Deprescribing.org
A resource for guideline developers to share their guidelines and for guideline users to access deprescribing guidance. This public-facing central repository is a place where deprescribing guideline…
deprescribing.org
December 2, 2025 at 5:02 PM
Gabapentinoid #deprescribing guidelines are being currently developed by Danijela Gnjidic's team at @sydney.edu.au. Find their project listed on our Deprescribing Guidelines Repository (DEPOT) here:
buff.ly/OCTfpeI
buff.ly/OCTfpeI
Reposted
2/ Objectives:
✅ Understand how racemic drugs & single-enantiomer versions compare in real clinical outcomes by reviewing RCT evidence
✅ Critically evaluate manufacturer claims about superiority of single-enantiomer 💊 in light of study quality, risk of bias, pt-important outcomes
#DrugEvidence25
✅ Understand how racemic drugs & single-enantiomer versions compare in real clinical outcomes by reviewing RCT evidence
✅ Critically evaluate manufacturer claims about superiority of single-enantiomer 💊 in light of study quality, risk of bias, pt-important outcomes
#DrugEvidence25
October 31, 2025 at 5:36 PM
2/ Objectives:
✅ Understand how racemic drugs & single-enantiomer versions compare in real clinical outcomes by reviewing RCT evidence
✅ Critically evaluate manufacturer claims about superiority of single-enantiomer 💊 in light of study quality, risk of bias, pt-important outcomes
#DrugEvidence25
✅ Understand how racemic drugs & single-enantiomer versions compare in real clinical outcomes by reviewing RCT evidence
✅ Critically evaluate manufacturer claims about superiority of single-enantiomer 💊 in light of study quality, risk of bias, pt-important outcomes
#DrugEvidence25